Marsh J D, Antman E M
Cardiovasc Drugs Ther. 2000 Oct;14(5):459-61. doi: 10.1023/a:1007820919574.
The T-type calcium channel offers a new therapeutic target for treatment of patients with cardiovascular disease. Mibefradil, a T channel blocker, produces heart rate slowing and coronary vasodilatation but without the negative inotropic effect commonly seen when L-type channel blockers are used. The present study shows Mibefradil prevents ischemic episodes that are and are not preceded by an increase in heart rate. Although Mibefradil has been withdrawn because of multiple drug interactions, new T-type calcium channel blockers are under development.
T型钙通道为心血管疾病患者的治疗提供了一个新的治疗靶点。米贝拉地尔是一种T通道阻滞剂，可使心率减慢并使冠状动脉扩张，但不会产生使用L型通道阻滞剂时常见的负性肌力作用。本研究表明，米贝拉地尔可预防有或没有心率增加先兆的缺血发作。尽管米贝拉地尔因多种药物相互作用已被撤市，但新型T型钙通道阻滞剂正在研发中。
